Skip to content
Open access

A bio-orthogonally engineered probiotic-T cell chimera amplifies adoptive cell therapy through spatial DC-T cell immune licensing.

Sep 2026 · Science Bulletin · 0 citations · 56 references
Medicine

TL;DR

Mechanistically, T-FOLactis promoted dendritic cell (DC)-T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18, establishing a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.

Abstract

Adoptive cell transfer (ACT) has achieved durable clinical responses in hematological malignancies, yet remains limited in solid tumors owing to poor T cell infiltration, inadequate persistence, and tumor-driven immunosuppression. Here, we report a bio-orthogonally engineered probiotic-T cell chimera (T-FOLactis) that creates a mutually reinforcing cellular-microbial system, in which FOLactis, an engineered Lactococcus lactis expressing a Flt3L-OX40L fusion protein, provides localized immunostimulatory cues to enhance T cell activation and effector function, while adoptively transferred T cells serve as cytotoxic effectors and mobile carriers that facilitate delivery of the bacterial payload to the tumor microenvironment. Using strain-promoted azide-alkyne cycloaddition chemistry, FOLactis bacteria were covalently anchored onto the surface of T cells, generating a cell-bound platform for spatially restricted immune modulation. In syngeneic colorectal cancer models, T-FOLactis reduced tumor burden by 78.1% compared with saline-treated controls and by 65.0% relative to conventional ACT, while prolonging median survival from 22 to 46 d without overt systemic toxicity. Mechanistically, T-FOLactis promoted dendritic cell (DC)-T cell proximity and established a spatially organized immune-licensing niche that amplified the functional impact of FOLactis-induced inflammatory cues, including IL-18. This spatial configuration was associated with enhanced coupling of cytokine availability, DC maturation, local co-stimulation and cytotoxic CD8+ T cell effector programming. IL-18 blockade impaired this licensing program and reduced therapeutic benefit, supporting IL-18 as a key functional mediator within the DC-T cell licensing niche. Together, these findings establish a modular cell-surface engineering strategy for augmenting ACT in colorectal cancer through coordinated immune network engagement.

Read PDF

Similar papers

Open access Sep 2026

Engineered probiotics for tumor-targeted combination chemoimmunotherapy

The approach integrates enzyme/prodrug therapy and immunotherapy into a single bacterial delivery system, overcoming key limitations of conventional therapies by providing a rationally designed framework for spatially controlled chemoimmunotherapy.

Zao-Feng Yang, Jong-Seong Im, Noah Chen et al. · 0 citations
Aug 2026

Tumor-tropic E. coli engineered as living T and NK cell engagers

LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestrati...

Shao-Bo Yang, Anna Clara Bader, S. Sendker et al. · 0 citations
Open access Sep 2026

Supramolecular immunomodulatory hydrogelator potentiates CAR-T therapy with long-lasting endogenous immunity toward solid tumor eradication

The success of chimeric antigen receptor (CAR)-T cell therapy in hematologic malignancies has not been translated to solid tumors, primarily due to inadequate T cell infiltration and an immunosuppressive tumor microenvironment that drives T cell exhaustion. To address these challenges, we developed a tailored immunomod...

Chen-Wei Jiang, Ming-Lu Tang, Ming-Mei Guo et al. · 0 citations
Aug 2026

Engineering Nonpathogenic Bacteria for Synergistic Tumor-Targeted Protein Degradation and Immunotherapy by Checkpoint-Inhibiting Nanobodies.

In vivo administration of engineered microbes led to marked tumor growth inhibition in both subcutaneous breast and orthotopic hepatocellular carcinoma models, along with prolonged animal survival, driven by remodeling of the suppressive tumor microenvironment through coordinated crosstalk between M1-like macrophages a...

Xinping Hu, Yu Chen, Meiyuan Jin et al. · 0 citations
Review Aug 2026

Ex vivo live macrophage engineering strategies in immunotherapy.

Recent strategies that reprogram and stabilize engineered macrophage phenotypes within the disease environment, and enhance targeting, retention, and contact-dependent functions through engineered recognition modules are reviewed.

Eunha Kim, Min-A Park, Kyobum Kim · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.